NGF

DRUG4 trials

Sponsors

Dompé Farmaceutici S.p.A, Aalborg University

Conditions

Dry EyeHealthy SubjectsHyperalgesiaPain Response

Early Phase 1

Spread of Muscle Hyperalgesia and Pain in a Low Dose NGF-induced Pain Model

CompletedNCT03217942

Aalborg UniversityHealthy Subjects, Hyperalgesia

Start: 2017-07-01End: 2017-10-01Updated: 2018-01-11

Interaction Between NGF and Acute Exercise-induced Ischemia

CompletedNCT03470038

Aalborg UniversityHealthy Subjects, Hyperalgesia, Pain Response

Start: 2018-03-15End: 2018-06-15Updated: 2019-02-15

Exercise-induced Ischemia and the Influence of Pain Modulation in a Nerve Growth Factor (NGF) Model

Aalborg UniversityHealthy Subjects, Hyperalgesia, Pain Response

Start: 2019-02-18End: 2019-06-30Target: 20Updated: 2019-02-18

Phase 2

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

CompletedNCT03019627

Dompé Farmaceutici S.p.ADry Eye

Start: 2017-01-20End: 2017-08-31Updated: 2019-02-08

Related Papers

Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.

2024-07-177 citations

Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study

British Journal of Ophthalmology2019-04-0364 citations